Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Paclitaxel, Cisplatin, 5-FU and Radiation in Esophageal Cancer
NCT00021320Phase 2Completed
- Sponsor
- Fox Chase Cancer Center
- Start
- May 2000
- Primary completion
- Jan 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in esophageal cancer, sponsored by Fox Chase Cancer Center. Primary endpoints: Disease-Free Survival at 2 years and Overall Survival at 2 years. Started May 2000; status: completed.
02
Drugs
paclitaxel
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT00021320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00021320.